--New appointments continue to strengthen diagnostics product development business--
NEW HAVEN, Conn., Dec. 17 /PRNewswire/ -- HistoRx, Inc., announced today that it has appointed Kathleen Q. Adams to the newly created position of Vice President, Diagnostics Marketing and has retained Stephen D. Chubb as a Strategic Advisor to the company.
Ms. Adams brings to HistoRx 20 years of marketing experience in the diagnostics and pharmaceuticals industries. Before joining HistoRx, she was Marketing Director of New Technology Planning & Research for Quest Diagnostics, following her appointment there as Director of Oncology Marketing. Previously, Ms. Adams held various positions in product management at Parke-Davis Pharmaceuticals, Schering-Plough, and Genetics Institute (now a division of Wyeth). She holds an M.B.A. from the Yale School of Management.
“I am excited to join HistoRx at this pivotal point in its development and ready to lead the company’s marketing efforts,” said Ms. Adams. “Within the next few years, we expect HistoRx’s diagnostic products will provide oncologists and their patients with important new tools for making key treatment decisions in a variety of cancer indications.”
Steve Chubb is a seasoned executive with more than 30 years of experience in the medical products and biotechnology industries. In his role as Strategic Advisor, he will assist HistoRx in identifying and assessing business development initiatives and opportunities. Most recently, Mr. Chubb was Founder, Chairman, and CEO of Matritech, Inc., a cancer diagnostics company that he created, took public, and sold to a world-leading point-of-care diagnostics company. Prior to that, he held the positions of CEO and Chairman of T Cell Sciences, Inc. and CEO and Chairman of Cytogen Corp. Mr. Chubb holds an M.B.A. from the Kellogg School of Management at Northwestern University and is a graduate of the U.S. Naval Academy.
“The HistoRx technologies for measuring protein in tissue in a quantitative, localized, and reproducible way represent the near-term future of cancer diagnostics, and the AQUA(R) system enables HistoRx to do this in a way no other company can,” said Mr. Chubb. “I am pleased to help the company realize its substantial commercial potential.”
Rana K. Gupta, CEO of HistoRx, commented, “We are very pleased to have Kate and Steve join the company. Their combination of diagnostics industry expertise and general management experience will be of tremendous benefit to the HistoRx management team. With Kate’s and Steve’s leadership, the company is well positioned for future growth and success.”
About HistoRx (www.historx.com)
HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care. The company’s products and services are based on proprietary AQUA(R) tissue biomarker analysis technology. AQUA(R) is the only platform capable of precisely measuring protein biomarker concentration with subcellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decisionmaking. HistoRx helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases. These partnerships provide the foundation for HistoRx to develop proprietary companion diagnostic tests that HistoRx will co-market with its partners’ targeted therapeutics. HistoRx also pursues internal programs to develop a pipeline of proprietary standard-of-care diagnostic products targeting improved treatment decisionmaking and patient outcomes in cancer care.
CONTACT: Thomas Gerson, Chief Financial Officer of HistoRx, Inc.,
+1-203-498-7500
Web site: http://www.historx.com/
